Paolo Manzoni

ORCID: 0000-0003-1340-3493
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neonatal Respiratory Health Research
  • Neonatal and Maternal Infections
  • Respiratory viral infections research
  • Infant Nutrition and Health
  • Antifungal resistance and susceptibility
  • Pneumonia and Respiratory Infections
  • Congenital Diaphragmatic Hernia Studies
  • Cystic Fibrosis Research Advances
  • Infant Development and Preterm Care
  • Tracheal and airway disorders
  • Neonatal Health and Biochemistry
  • COVID-19 Impact on Reproduction
  • Infant Health and Development
  • Retinopathy of Prematurity Studies
  • Fungal Infections and Studies
  • Pediatric Hepatobiliary Diseases and Treatments
  • Congenital Heart Disease Studies
  • Nosocomial Infections in ICU
  • Streptococcal Infections and Treatments
  • Antibiotics Pharmacokinetics and Efficacy
  • Viral gastroenteritis research and epidemiology
  • Sepsis Diagnosis and Treatment
  • Breastfeeding Practices and Influences
  • COVID-19 and healthcare impacts
  • Ultrasound in Clinical Applications

Ospedale degli Infermi
2019-2025

University of Turin
2005-2025

Ospedale Sant'Anna
2011-2024

Ospedale degli Infermi
2019-2023

ASL Roma
2023

Infant
2019-2020

AOL (United States)
2020

Pension Fund for Care and Well-Being
2019

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2015-2018

University of Liverpool
2018

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention RSV healthy infants. Nirsevimab monoclonal antibody with an extended half-life that being developed to protect infants entire season single intramuscular dose.

10.1056/nejmoa1913556 article EN New England Journal of Medicine 2020-07-29

<h3>Context</h3>Sepsis is a common and severe complication in premature neonates, particularly those with very low birth weight (VLBW) (&lt;1500 g). Whether lactoferrin, mammalian milk glycoprotein involved innate immune host defenses, can reduce the incidence of sepsis unknown. In animal models, probiotic Lactobacillus rhamnosus GG (LGG) enhances activity lactoferrin but has not been studied human infants.<h3>Objective</h3>To establish whether bovine (BLF), alone or combination LGG, reduces...

10.1001/jama.2009.1403 article EN JAMA 2009-10-06

Invasive candida infections are a major cause of morbidity and mortality in preterm infants. We performed multicenter, randomized, double-blind, placebo-controlled trial fluconazole for the prevention fungal colonization infection very-low-birth-weight neonates.

10.1056/nejmoa065733 article EN New England Journal of Medicine 2007-06-14

Background. Colonization by Candida species is the most important predictor of development invasive fungal disease in preterm neonates, and enteric reservoir a major site colonization. We evaluated effectiveness an orally supplemented probiotic (Lactobacillus casei subspecies rhamnosus; Dicoflor [Dicofarm spa]; 6 × 109 cfu/day) prevention gastrointestinal colonization preterm, very low birth weight (i.e., <1500-g) neonates during their stay neonatal intensive care unit. Methods. Over...

10.1086/504324 article EN Clinical Infectious Diseases 2006-05-18

OBJECTIVE. Colonization by Candida spp is a major risk factor for development of fungal sepsis, but little known about the variables associated with progression to invasive disease in already colonized neonates. We investigated such large number preterm neonates an NICU. SETTING. This study was conducted Department Neonatology and NICU at Sant'Anna Hospital Torino, Italy. DESIGN AND PATIENTS A database search clinical charts weekly surveillance cultures used identify all birth weights...

10.1542/peds.2006-1311 article EN PEDIATRICS 2006-12-01

Acute bronchiolitis is the leading cause of lower respiratory tract infection and hospitalization in children less than 1 year age worldwide. It usually a mild disease, but some may develop severe symptoms, requiring hospital admission ventilatory support ICU. Infants with pre-existing risk factors (prematurity, bronchopulmonary dysplasia, congenital heart diseases immunodeficiency) be predisposed to form disease. Clinical diagnosis manly based on medical history physical examination...

10.1186/1824-7288-40-65 article EN cc-by ˜The œItalian Journal of Pediatrics/Italian journal of pediatrics 2014-10-24

Lactoferrin is a mammalian milk glycoprotein involved in innate immunity. Recent data show that bovine lactoferrin (bLF) prevents late-onset sepsis preterm very low birth weight (VLBW) neonates.This secondary analysis of from multicenter randomized controlled trial where VLBW neonates randomly received bLF (100 mg/day; group A1), + Lactobacillus rhamnosus GG (10(6) colony-forming units per day; A2), or placebo (group B) for 6 weeks. Here we analyze the incidence rates fungal colonization,...

10.1542/peds.2011-0279 article EN PEDIATRICS 2011-12-20

Global assessment of antimicrobial agents prescribed to infants in the neonatal intensive care unit (NICU) may inform stewardship efforts.We conducted a one-day global point prevalence study all antimicrobials provided NICU infants. Demographic, clinical, and microbiologic data were obtained including level, census, birth weight, gestational/chronologic age, diagnoses, therapy (reason for use; length therapy), program (ASP), 30-day in-hospital mortality.On July 1, 2019, 26% (580/2,265;...

10.1016/j.eclinm.2021.100727 article EN cc-by-nc-nd EClinicalMedicine 2021-01-29

Respiratory syncytial virus (RSV) is a highly contagious seasonal and the leading cause of Lower Tract Infections (LRTI), including pneumonia bronchiolitis in children. RSV-related LRTI approximately 3 million hospitalizations 120,000 deaths annually among children <5 years age. The majority burden RSV occurs previously healthy infants. Only monoclonal antibody (mAb) has been approved against infections restricted group, leaving an urgent unmet need for large number potentially benefiting...

10.1080/21645515.2022.2079322 article EN cc-by-nc-nd Human Vaccines & Immunotherapeutics 2022-06-20
Coming Soon ...